A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
NCT03085914
Completed
This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as Treatment Groups A through G below (see Study Drug and Background Therapies, Dose, and Mode of Administration). Phase 1 consisted of a 3 + 3 + 3 design intended to determine the MTD or PAD of epacadostat when given in combination with pembrolizumab and chemotherapy; effica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
NCT01319981
Completed
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if intensive chemotherapy (hyper-CVAD therapy) given in combination with liposomal vincristine (Marqibo), in addition to rituximab for patients who are CD20 positive and/or imatinib, dasatinib, or ruxolitinib for patients with the Philadelphia (Ph) chromosome, can help to control ALL or lymphoblastic lymphoma. The safety of this treatment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2022
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
NCT03036904
Completed
This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/23/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Register for Updates
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
NCT00822120
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxygluc... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/16/2022
Locations: Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas +1 locations
Conditions: Lymphoma, Nonneoplastic Condition
Register for Updates
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NCT00087178
Completed
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating breast cancer. PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens to compare how well they work in treating women who have undergone surgery for breast cancer that has not spre... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/10/2022
Locations: Texas Oncology - Midtown Austin, Austin, Texas +8 locations
Conditions: Breast Cancer
Register for Updates
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
NCT04596033
Terminated
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, Genocea confirms which cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune cells that recognize these cancer proteins are multiplied many times (a process called PLANET™) to create a personalized GEN-011 cell therapy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/13/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Register for Updates
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
NCT02529813
Completed
This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and... Read More
Gender:
ALL
Ages:
Between 1 year and 80 years
Trial Updated:
06/29/2022
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive, Minimal Residual Disease, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Register for Updates
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
NCT01966471
Completed
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2022
Locations: The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas
Conditions: Breast Cancer
Register for Updates
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
NCT01247701
Completed
In this study, the investigators will use busulfan and cyclophosphamide (BuCy) backbone with the addition of fludarabine as the preparative Stem Cell Transplant (SCT) regimen. As an attempt to improve engraftment rate and reduce infections, the investigators are going to incorporate fludarabine in the conditioning regimen. The use of a BuCy backbone has been widely used and comparable to total body irradiation and cyclophosphamide (Cy/TBI) regimen. Encouraging data on adding fludarabine to the... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/13/2022
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Myeloid Hematological Malignancies
Register for Updates
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NCT01547741
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/13/2022
Locations: Texas Cancer Center, Abilene, Texas +34 locations
Conditions: Breast Cancer
Register for Updates
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NCT00887536
Completed
The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this stud... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
04/13/2022
Locations: Texas Cancer Center - Abilene South, Abilene, Texas +56 locations
Conditions: Breast Cancer
Register for Updates
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
NCT00567567
Completed
This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments before a... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/01/2022
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas +6 locations
Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates